汉康资本

汉康资本（原“上海建信资本”）是专注于生物医药行业的创业投资基金，致力于生物医药、诊断试剂、以及医疗器械等领域的投资。公司聚焦于重大疾病和重大临床需求，开展深入研究，提前布局具有一流团队和技术平台的创业公司，并在产品管线、团队组建、申报注册、临床试验等方面提供专业的见解、经验和资源，推动其早日成为行业龙头企业。公司成立至今，先后投资的公司有：北京东方百泰、北京诺诚健华、上海和誉生物、苏州韬略、深圳微芯生物、中山康方生物、厦门力品药业、武汉海特生物（代码:300683）等行业龙头公司。汉康资本获得清科集团颁发的“创业投资机构100强”、“医疗健康领域投资机构20强”。Hankang Capital is a venture capital firm focusing on the healthcare industry including biotech, IVD, medical device, etc.The company focuses on the in-depth research in major diseases and unmet clinical needs , promoting the establishment of startups with first-tier teams and technology platforms. Jianxin also provides professional insights, experience, and resources in product pipelines, team formation, application for registration, and clinical trials, to promote the startups becoming an industry leader.Since the establishment of the company，Jianxin has invested in Eastern Biotech, Innocare, Abbisko Therapeutics, Teligene Ltd, Chipscreen, Akeso Biopharma, LP Pharma，Wuhan Hiteck(code: 300683),etc which are the leaders in the industry.Hankang Capital was awarded‘Top 100 Venture Capital Institutions’and‘Top 20 Investment Institutions in the Healthcare Sector’issued by Zero2IPO Group.